| Here's Why You Should Add DexCom Stock to Your Portfolio Now |
DXCM continues to raise investor optimism due to its strong product portfolio. |
zacks.com |
2025-05-16 13:01:08 |
Czytaj oryginał (ang.) |
| 5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil |
Five high-flying medical instrument stocks are: DXCM, IDXX, NPCE, CLPT, FMS. |
zacks.com |
2025-05-15 13:11:13 |
Czytaj oryginał (ang.) |
| Top Health & Fitness Stocks to Buy for the Wellness Boom |
The health and fitness boom is fueling demand for gyms, nutrition, and wellness services. Stocks like SFM, HIMS and DXCM are well-positioned to benefit. |
zacks.com |
2025-05-14 14:01:25 |
Czytaj oryginał (ang.) |
| Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO |
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO. |
businesswire.com |
2025-05-13 12:30:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About DexCom (DXCM) Rating Upgrade to Buy |
DexCom (DXCM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-05-12 17:05:40 |
Czytaj oryginał (ang.) |
| Buy 5 Health and Fitness Stocks to Enhance Your Portfolio Returns |
Five Health and Fitness stocks to buy now are: SFM, DXCM, HIMS, UNFI, GDRX. |
zacks.com |
2025-05-12 14:10:52 |
Czytaj oryginał (ang.) |
| DexCom Q1 Earnings: Organic Revenue Growth Versus Cost Pressure |
DexCom's Q1 2025 earnings show strong growth potential, but cost pressures are impacting margins, leading me to lower my rating from buy to hold. Despite demographic tailwinds and a growing market, gross margin declines and cost pressures present significant downside risks. My updated DCF analysis yields a price target of $92.90 for DXCM stock, only a 9% upside from current prices, reducing the margin of safety. |
seekingalpha.com |
2025-05-09 15:00:41 |
Czytaj oryginał (ang.) |
| DexCom Stock: Earnings Beat and New Market Access Drive Bull Case |
DexCom, Inc. NASDAQ: DXCM has once again demonstrated its formidable position in the continuous glucose monitoring (CGM) market, delivering outstanding first-quarter 2025 financial results that underscore its sustained momentum. The company's performance, driven by strong product demand, successful innovation, and strategic market access expansion, strongly supports an ambitious trajectory for the remainder of 2025, indicating a clear path towards further solidifying its leadership in diabetes technology. |
marketbeat.com |
2025-05-08 11:31:51 |
Czytaj oryginał (ang.) |
| 5 Best Stocks of the S&P 500 ETF in the Past Month |
The S&P 500 is enjoying its longest winning streak since 2004. We have highlighted the five best stocks in the S&P 500 over the past month. |
zacks.com |
2025-05-05 15:50:39 |
Czytaj oryginał (ang.) |
| DexCom: Growth Is Reaccelerating But Don't Ignore The Risks |
I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, establishing a reaccelerating trend in growth for the company. However, DXCM's competitor product, Abbott's Libre Freestyle, has been growing faster despite larger sales. |
seekingalpha.com |
2025-05-05 08:34:04 |
Czytaj oryginał (ang.) |
| DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins |
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets. |
zacks.com |
2025-05-02 18:25:33 |
Czytaj oryginał (ang.) |
| Nasdaq Index: Dexcom, Meta, ON Semi Lead US Stocks Rebound on Trade Optimism |
Nasdaq jumps as Dexcom, Palantir, and ON Semi soar. Jobs report beats forecasts, easing inflation fears and driving US stock market optimism. |
fxempire.com |
2025-05-02 17:43:14 |
Czytaj oryginał (ang.) |
| Dexcom Stock Is Today's Big Winner After Earnings. Why the Medtech Is Soaring. |
Dexcom, the maker of glucose monitors for patients with diabetes, reports a strong first quarter. |
barrons.com |
2025-05-02 15:53:00 |
Czytaj oryginał (ang.) |
| 2 Growth Stocks to Buy and Hold for a Decade |
Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock market. While it's a perfectly human reaction to volatility, it's a tendency investors should avoid. |
fool.com |
2025-05-02 08:16:00 |
Czytaj oryginał (ang.) |
| DexCom, Inc. (DXCM) Q1 2025 Earnings Call Transcript |
DexCom, Inc. (NASDAQ:DXCM ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Sean Christensen - VP, Finance & IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, CFO & Chief Accounting Officer Jacob Leach - EVP & COO Conference Call Participants Matt Taylor - Jefferies Robbie Marcus - JPMorgan Danielle Antalffy - UBS Jeff Johnson - Baird Jayson Bedford - Raymond James Travis Steed - Bank of America Merrill Lynch Matt O'Brien - Piper Sandler Marie Thibault - BTIG Joanne Wuensch - Citibank Michael Polark - Wolfe Research Margaret Andrew - William Blair Mike Kratky - Leerink Partners Colin Clark - Stifel, Nicolaus & Company Issie Kirby - Redburn Bill Plovanic - Canaccord Chris Pasquale - Nephron Steve Lichtman - Oppenheimer & Co. Matt Miksic - Barclays Anthony Petrone - Mizuho Group Operator Welcome to the DexCom First Quarter 2025 Earnings Release Conference Call. My name is Louella, and I will be your operator for today's call. |
seekingalpha.com |
2025-05-02 01:04:03 |
Czytaj oryginał (ang.) |
| Compared to Estimates, DexCom (DXCM) Q1 Earnings: A Look at Key Metrics |
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-01 22:30:39 |
Czytaj oryginał (ang.) |
| DexCom (DXCM) Q1 Earnings Miss Estimates |
DexCom (DXCM) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.32 per share a year ago. |
zacks.com |
2025-05-01 22:20:45 |
Czytaj oryginał (ang.) |
| Dexcom beats quarterly sales estimates, reiterates annual forecast |
Medical device maker Dexcom beat first-quarter sales estimates helped by strong demand for its continuous glucose monitors (CGMs) used by patients with diabetes. |
reuters.com |
2025-05-01 20:54:11 |
Czytaj oryginał (ang.) |
| Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program |
SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program. |
businesswire.com |
2025-05-01 20:02:00 |
Czytaj oryginał (ang.) |
| MedTech Stocks' Earnings to Watch on May 1: BDX, CAH, BAX, DXCM & SYK |
This earnings season so far has reflected a continued recovery in sales for companies within the Medical sector. Earnings have increased year over year, albeit at a slower pace than revenues. |
zacks.com |
2025-04-30 15:55:39 |
Czytaj oryginał (ang.) |
| Got $200? 2 Healthcare Stocks to Buy and Hold Forever |
Healthcare is considered a defensive industry, since good medical care is needed regardless of economic or market conditions. Therefore many companies in this sector are somewhat insulated from the impact of economic downturns. |
fool.com |
2025-02-26 06:32:00 |
Czytaj oryginał (ang.) |
| Quality Key in Volatile Market, NFLX & DXCM Value Plays |
Friday's trading session showed weakness is possible in the current market, and Lisa Schreiber says investors need to turn to quality in a time of volatility. Lisa expects the U.S. economy to bolster strength but suggest investors bring an "umbrella' to protect their portfolios. |
youtube.com |
2025-02-21 17:48:57 |
Czytaj oryginał (ang.) |
| 4 Seniors & Aging Demographics Stocks to Watch Right Now |
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare. |
zacks.com |
2025-02-21 14:10:31 |
Czytaj oryginał (ang.) |
| NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight |
ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management. |
zacks.com |
2025-02-18 15:36:09 |
Czytaj oryginał (ang.) |
| Analyst Cautiously Optimistic On DexCom As Competitive Pressures Loom |
On Thursday, Dexcom, Inc.'s DXCM fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. |
benzinga.com |
2025-02-14 17:04:25 |
Czytaj oryginał (ang.) |
| DexCom Analysts Increase Their Forecasts After Q4 Earnings |
DexCom, Inc. DXCM reported weaker-than-expected earnings for its fourth quarter on Thursday. |
benzinga.com |
2025-02-14 11:22:10 |
Czytaj oryginał (ang.) |
| DexCom Stock Rises Despite Q4 Earnings Miss & Lower Margins |
DXCM's fourth-quarter 2024 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets. |
zacks.com |
2025-02-14 09:56:06 |
Czytaj oryginał (ang.) |
| DexCom, Inc. (DXCM) Q4 2024 Earnings Call Transcript |
DexCom, Inc. (NASDAQ:DXCM ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sean Christensen - Vice President of Finance and Investor Relations Kevin Sayer - Chairman, President and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Jake Leach - Chief Operating Officer Conference Call Participants Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Robbie Marcus - J.P. Morgan Danielle Antalffy - UBS Travis Steed - Bank of America Joanne Wuensch - Citibank Matt Taylor - Jefferies Matthew O'Brien - Piper Sandler Jayson Bedford - Raymond James Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Steve Lichtman - Oppenheimer Issie Kirby - Redburn-Atlantic Michael Polark - Wolfe Research Patrick Wood - Morgan Stanley Sam Eiber - BTIG Mike Kratky - Leerink Operator Thank you for standing by. |
seekingalpha.com |
2025-02-13 23:33:09 |
Czytaj oryginał (ang.) |
| DexCom: Revenue Up, EPS Misses Mark |
DexCom (DXCM 0.26%), known for its continuous glucose monitoring (CGM) systems, recently unveiled its Q4 2024 earnings report on Feb. 13, 2025. This release highlighted an 8% growth in revenue, which reached $1.114 billion, slightly exceeding analysts' expectations of $1.112 billion. |
fool.com |
2025-02-13 21:02:47 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About DexCom (DXCM) Q4 Earnings |
The headline numbers for DexCom (DXCM) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-13 20:30:19 |
Czytaj oryginał (ang.) |
| DexCom (DXCM) Misses Q4 Earnings Estimates |
DexCom (DXCM) came out with quarterly earnings of $0.45 per share, missing the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.50 per share a year ago. |
zacks.com |
2025-02-13 20:15:24 |
Czytaj oryginał (ang.) |
| Dexcom beats fourth-quarter sales, reiterates 2025 revenue forecast |
Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes. |
reuters.com |
2025-02-13 19:09:07 |
Czytaj oryginał (ang.) |
| Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations |
Dexcom stock fell late Thursday after the company missed fourth-quarter profit expectations by a nickel per share. The post Dexcom Tumbles As Fourth-Quarter Profit Lags Expectations appeared first on Investor's Business Daily. |
investors.com |
2025-02-13 18:12:11 |
Czytaj oryginał (ang.) |
| DXCM Q4 Earnings to Reflect Market Expansion & Stelo Impact? |
DexCom Q4 results are likely to reflect strong growth on the back of U.S. sales expansion, global gains and Stelo traction, driving momentum and market expansion into 2025. |
zacks.com |
2025-02-11 09:21:24 |
Czytaj oryginał (ang.) |
| Countdown to DexCom (DXCM) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS |
Evaluate the expected performance of DexCom (DXCM) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2025-02-10 12:21:22 |
Czytaj oryginał (ang.) |
| Should You Buy DexCom Stock Before Feb. 13? |
DexCom (DXCM 1.51%) is a healthcare company that makes continuous glucose monitoring (CGM) devices, which help people track glucose levels. |
fool.com |
2025-02-06 11:30:00 |
Czytaj oryginał (ang.) |
| Prediction: This Top Growth Stock Will Outperform the Market in the Next Decade |
Medical device specialist DexCom (DXCM -0.90%) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to unimpressive financial results, especially in the second and third quarters. |
fool.com |
2025-02-03 11:15:00 |
Czytaj oryginał (ang.) |
| Got $2,000? 2 Top Growth Stocks to Buy and Hold for Years |
The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the performance of many top stocks reflects this reality. However, a share price moving upward or downward should never be the sole reason you buy (or sell) stocks. |
fool.com |
2025-02-03 10:45:00 |
Czytaj oryginał (ang.) |
| Dexcom Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call for February 13, 2025 at 4:30 p.m. Eastern Time. |
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2024 financial results after market close on Thursday, February 13, 2025. Management will hold a conference call to review the company's fourth quarter and fiscal year 2024 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations webs. |
businesswire.com |
2025-01-30 10:30:00 |
Czytaj oryginał (ang.) |
| DXCM's Preliminary Results Show Strong Growth: How to Play the Stock? |
DexCom Inc. DXCM is off to a strong start in 2025, with its stock rallying 5.7% following the release of its preliminary results for the fourth quarter and fiscal 2024 on Jan. 13, 2025. The company's robust performance has reaffirmed investor confidence, driven by impressive revenue growth and a promising outlook for 2025. |
zacks.com |
2025-01-21 13:50:22 |
Czytaj oryginał (ang.) |
| These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024 |
Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market. Many outliers were in the tech sector, so it's worth taking a look at the tech-heavy Nasdaq-100 index. |
fool.com |
2025-01-04 09:45:00 |
Czytaj oryginał (ang.) |
| Abbott and DexCom settle glucose monitor patent disputes |
Abbott Laboratories said on Monday it and DexCom have reached an agreement to settle all patent disputes between the companies related to continuous glucose monitoring devices. |
reuters.com |
2024-12-23 18:17:36 |
Czytaj oryginał (ang.) |
| DexCom (DXCM) Soars 5.6%: Is Further Upside Left in the Stock? |
DexCom (DXCM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term. |
zacks.com |
2024-12-23 09:31:07 |
Czytaj oryginał (ang.) |
| 1 Reason to Sell DexCom Stock, and 1 Reason to Buy |
Shares of the medical-device maker DexCom (DXCM 5.57%) are down by 37% this year. The diabetes-focused healthcare company disappointed investors with its second-quarter results, leading to a massive drop in its stock price overnight. |
fool.com |
2024-12-21 08:45:00 |
Czytaj oryginał (ang.) |
| 2025 Picks: 2 Stocks to Buy Now for 50% Upside |
Two S&P 500 stocks--DexCom and Albemarle--are already on sale for investors to buy in 2025. |
zacks.com |
2024-12-20 11:01:16 |
Czytaj oryginał (ang.) |
| Diabetes Brands Dexcom, Ozempic, Mounjaro Drive Q3 Convergent TV Ad Engagement |
NEW YORK--(BUSINESS WIRE)--EDO, the TV outcomes company, has released its Q3 2024 Diabetes Convergent TV Outcomes Report, providing critical insights into the diabetes category linear and streaming TV ad performance. The report reveals actionable findings on what drives consumer engagement in this category, with GLP-1 drugs reshaping the landscape of diabetes management and advertisers increasingly investing in convergent TV to target this growing audience. Consumer engagement – measured by act. |
businesswire.com |
2024-12-19 10:30:00 |
Czytaj oryginał (ang.) |
| DXCM Stock Gains on the Launch of Proprietary Generative AI Platform |
Dexcom announces the first Generative AI platform in glucose biosensing. |
zacks.com |
2024-12-18 13:35:16 |
Czytaj oryginał (ang.) |
| Dexcom's over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels |
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI platform with technology from Google Cloud. |
cnbc.com |
2024-12-17 11:00:01 |
Czytaj oryginał (ang.) |
| Dexcom Launches the First Generative AI Platform in Glucose Biosensing |
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today it has launched a proprietary Generative AI (GenAI) platform, making Dexcom the first CGM manufacturer to integrate GenAI into glucose biosensing technology.1 The new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. Stelo,. |
businesswire.com |
2024-12-17 11:00:00 |
Czytaj oryginał (ang.) |
| Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM |
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing technology, is proud to announce that the Dexcom G7 Continuous Glucose Monitoring (CGM) System has now been added to the Alberta Drug Benefit List. In addition, the Alberta government has expanded the eligibility criteria* to also include adults ages 18 and older. Alberta residents living with type 1 or type 2 diabetes who are enrolled in a government-sponsored health benefit plan† and. |
businesswire.com |
2024-12-17 10:00:00 |
Czytaj oryginał (ang.) |
| Here's Why You Should Retain DexCom Stock in Your Portfolio for Now |
DXCM continues to raise optimism among investors owing to its strong product portfolio. |
zacks.com |
2024-12-13 11:01:16 |
Czytaj oryginał (ang.) |
| DexCom: Brighter 2025 From Stelo Ramp |
DexCom faces challenges in 2024 due to competition and missteps, but the long-term outlook for continuous glucose monitors remains strong. Q3 revenue grew only 2% y/y to $994.2 million, with temporary and long-lasting headwinds impacting growth and margins. The new over-the-counter Stelo CGM launched in August, offering a new growth vector and targeting non-insulin users, with significant ramp-up expected in 2025. |
seekingalpha.com |
2024-12-10 17:18:54 |
Czytaj oryginał (ang.) |
| 11 Ultra SWAN Bargains That Could Thrive As The Market Soars To Record Highs |
The S&P is up 27% in 2024, including a 5.5% rally in November. The Euphoria index is at record highs, indicating investor sentiment is extremely bullish. While 2025 is likely to see much larger volatility, there are still many excellent blue-chip opportunities to buy for a potentially significant 2025. Here are 11 Ultra Sleep Well At Night quality companies that are 45% undervalued, growing at 18%, with an 85% average fundamentally justified return potential in 2025. |
seekingalpha.com |
2024-12-05 09:00:00 |
Czytaj oryginał (ang.) |
| 3 Reasons to Buy DexCom Stock Like There's No Tomorrow |
Medical device specialist DexCom (DXCM -0.14%) is going through a rough patch. The company's shares are down sharply year to date due to unimpressive financial results -- and some of the headwinds it has encountered are, no doubt, concerning. |
fool.com |
2024-12-02 11:12:00 |
Czytaj oryginał (ang.) |
| 2 Excellent Healthcare Stocks to Hold Through the Next Decade |
Although excellent medical care is always in high demand, the healthcare sector continuously evolves. Companies aren't automatically worth investing in just because they provide essential medical services. |
fool.com |
2024-11-28 09:45:00 |
Czytaj oryginał (ang.) |
| Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2024-11-26 12:55:28 |
Czytaj oryginał (ang.) |
| These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over |
The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes ( S&P 500 , Nasdaq Composite, and Dow Jones), the Nasdaq-100 has grown in popularity over the years because of its concentration of tech stocks (almost 60%), many of which have seen their valuations skyrocket in recent years. |
fool.com |
2024-11-26 09:30:00 |
Czytaj oryginał (ang.) |
| 2 Superior Growth Stocks to Buy Right Now If You have $1,000 to Invest |
It's not always easy to be a long-term investor, particularly when contending with the natural cyclicality that the stock market presents if you buy and hold through bull as well as bear markets. |
fool.com |
2024-11-24 12:15:00 |
Czytaj oryginał (ang.) |
| DexCom and OURA Ink Partnership for Metabolic Health Innovation |
DXCM and smart ring maker, OURA, join forces to help individuals make informed decisions regarding diet, exercise and overall well-being. |
zacks.com |
2024-11-22 12:16:24 |
Czytaj oryginał (ang.) |
| DexCom Pairs Its Glucose Monitor With Oura's Smart Ring |
If you want to monitor your vital signs like an Olympic athlete, you should welcome a pact between glucose-monitor vendor DexCom and Oura smart rings. |
barrons.com |
2024-11-19 14:50:00 |
Czytaj oryginał (ang.) |